is now FDA cleared and available to order.

Visit PrecivityAD2.com for more details.

Clarity Through Innovation®

Developing and commercializing novel diagnostics for Alzheimer’s disease and related forms of neurodegeneration to improve treatment decisions and patients’ lives

State-of-the-art proprietary liquid-chromatography-tandem mass spectrometry (LC-MS/MS) methodologies
Blood tests to assess for brain amyloid pathology - The PrecivityAD® and PrecivityAD2® tests
Extensive domain expertise; leading neurological scientists and researchers on staff

Click on the video to learn more about the history of C2N Diagnostics and development of the Precivity™ blood tests for Alzheimer’s disease.

This is a test page